Tags

Type your tag names separated by a space and hit enter

Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
J Clin Psychiatry. 1997 Nov; 58(11):479-83.JC

Abstract

BACKGROUND

Clozapine is currently the treatment of choice for neuroleptic-resistant schizophrenia. Olanzapine is a new antipsychotic drug that has shown efficacy against positive and negative symptoms of schizophrenia, with minimal extrapyramidal side effects. However, the effectiveness of olanzapine has not yet been reported among treatment-refractory schizophrenic patients.

METHOD

A total of 25 schizophrenic patients (DSM-IV criteria) with documented lack of response to two conventional antipsychotic drugs entered this 6-week prospective, open-label treatment trial with olanzapine 15 to 25 mg/day. An optional extension up to 6 months was provided.

RESULTS

As a group, the olanzapine-treated patients showed statistically significant improvement (p < .05) in both positive and negative symptoms by the end of 6 weeks of therapy. Overall, 9 of the patients (36%) met the a priori criteria for treatment-response (> or = 35% decrease in Brief Psychiatric Rating Scale [BPRS] total score, plus posttreatment Clinical Global Impression-Severity < or = 3 or BPRS total < 18). Only one patient discontinued treatment because of an adverse event during the study. Despite the relatively high dosages of olanzapine used, there were no reports of parkinsonism, akathisia, or dystonia, and no patients required anticholinergic medication.

CONCLUSION

This open study suggests that olanzapine may be effective and well tolerated for a substantial number of neuroleptic-resistant schizophrenic patients. Further blinded, controlled trials are needed to confirm our results.

Authors+Show Affiliations

Hospital Universitario de Valme, Sevilla, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9413413

Citation

Martín, J, et al. "Olanzapine in Treatment-refractory Schizophrenia: Results of an Open-label Study. the Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia." The Journal of Clinical Psychiatry, vol. 58, no. 11, 1997, pp. 479-83.
Martín J, Gómez JC, García-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry. 1997;58(11):479-83.
Martín, J., Gómez, J. C., García-Bernardo, E., Cuesta, M., Alvarez, E., & Gurpegui, M. (1997). Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. The Journal of Clinical Psychiatry, 58(11), 479-83.
Martín J, et al. Olanzapine in Treatment-refractory Schizophrenia: Results of an Open-label Study. the Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J Clin Psychiatry. 1997;58(11):479-83. PubMed PMID: 9413413.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. AU - Martín,J, AU - Gómez,J C, AU - García-Bernardo,E, AU - Cuesta,M, AU - Alvarez,E, AU - Gurpegui,M, PY - 1997/12/31/pubmed PY - 1997/12/31/medline PY - 1997/12/31/entrez SP - 479 EP - 83 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 58 IS - 11 N2 - BACKGROUND: Clozapine is currently the treatment of choice for neuroleptic-resistant schizophrenia. Olanzapine is a new antipsychotic drug that has shown efficacy against positive and negative symptoms of schizophrenia, with minimal extrapyramidal side effects. However, the effectiveness of olanzapine has not yet been reported among treatment-refractory schizophrenic patients. METHOD: A total of 25 schizophrenic patients (DSM-IV criteria) with documented lack of response to two conventional antipsychotic drugs entered this 6-week prospective, open-label treatment trial with olanzapine 15 to 25 mg/day. An optional extension up to 6 months was provided. RESULTS: As a group, the olanzapine-treated patients showed statistically significant improvement (p < .05) in both positive and negative symptoms by the end of 6 weeks of therapy. Overall, 9 of the patients (36%) met the a priori criteria for treatment-response (> or = 35% decrease in Brief Psychiatric Rating Scale [BPRS] total score, plus posttreatment Clinical Global Impression-Severity < or = 3 or BPRS total < 18). Only one patient discontinued treatment because of an adverse event during the study. Despite the relatively high dosages of olanzapine used, there were no reports of parkinsonism, akathisia, or dystonia, and no patients required anticholinergic medication. CONCLUSION: This open study suggests that olanzapine may be effective and well tolerated for a substantial number of neuroleptic-resistant schizophrenic patients. Further blinded, controlled trials are needed to confirm our results. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/9413413/Olanzapine_in_treatment_refractory_schizophrenia:_results_of_an_open_label_study__The_Spanish_Group_for_the_Study_of_Olanzapine_in_Treatment_Refractory_Schizophrenia_ L2 - http://www.psychiatrist.com/jcp/article/pages/1997/v58n11/v58n1103.aspx DB - PRIME DP - Unbound Medicine ER -